ZMYND11 and prostate carcinoma: Together, these data demonstrate that ZMYND11 downregulation frequently occurs during prostate cancer tumor progression to an advanced stage and correlates with an unfavorable prognosis in prostate cancer patients, suggesting that ZMYND11 could act as a tumor suppressor and that its reduced expression may contribute to prostate cancer tumorigenesis and metastasis.